ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR vs. Surgery: A New Look at 1-Year Outcomes Among Moderate-Risk Patients with Severe, Symptomatic AS
Thursday, May 19, 2022
Submitted by
Source
Source Name: Cardiovascular Business
Transcatheter aortic valve replacement (TAVR) is not inferior to surgical aortic valve replacement (SAVR) when it comes to all-cause mortality after one year. This is among moderate-risk patients with severe, symptomatic aortic stenosis (AS). According to a new analysis published in JAMA, a close comparison revealed that each treatment option is associated with certain benefits over the other.
Printer-friendly
Comments